Показано 0 из 0
Дата |
---|
12.09.2023 |
18.08.2023 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
1 000.00
|
1 000.00
|
1 000.00
|
1 000.00
|
|
|
3 000.00
|
|
|
|
1 000.00
|
1 000.00
|
1 000.00
|
1 000.00
|
|
|
1 000.00
|
|
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.